How This Evidence Evolved
Sickle Cell Therapeutics
From hydroxyurea to gene therapy
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Median annual crises: 1.63 vs 2.98 (p=0.01) with crizanlizumab vs placebo
Hb increase >1 g/dL at week 24: voxelotor 1,500 mg 51% vs placebo 7%
Gene therapy mechanisms, conditioning-related adverse effects, and long-term follow-up considerations.
FDA approval of Casgevy and Lyfgenia for sickle cell disease on 8 December 2023.
Current standard of care and ongoing research directions
Landmark Trials in This Story
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia
Median annual painful crises: hydroxyurea 2.5 vs placebo 4.5 (p<0.001)
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
Median annual crises: 1.63 vs 2.98 (p=0.01) with crizanlizumab vs placebo
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Hb increase >1 g/dL at week 24: voxelotor 1,500 mg 51% vs placebo 7%
Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) for individuals 12 years and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOC): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG).
Gene therapy mechanisms, conditioning-related adverse effects, and long-term follow-up considerations.
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.
FDA approval of Casgevy and Lyfgenia for sickle cell disease on 8 December 2023.
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.